Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Nasdaq futures drop over 2% on concerns over AI buildout costs, Fed rate outlook
- Nasdaq 100 set to shed over $1 trillion as tech selloff deepens; SpaceX slides
- Oil prices fall as investors focus on Hormuz flows after peace talks
- SpaceX slides, tech stocks dip — what’s moving markets
- Deutsche Bank cuts gold outlook as Fed repricing weighs on prices
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Cullinan Oncology Inc. (CGEM) PT Lowered to $38 at Morgan Stanley
August 8, 2024 11:56 AM EDTMorgan Stanley analyst Jeffrey Hung lowered the price target on Cullinan Oncology Inc. (NASDAQ: CGEM) to $38.00 (from $40.00) while maintaining a Overweight rating.
The analyst comments "With earnings, Cullinan reported multiple updates across its portfolio. The biggest update is that the company will pursue rheumatoid arthritis (RA) as... More
